Efficacy of pegylated interferon plus ribavirin treatment in HIV/hepatitis C virus co-infected patients receiving abacavir plus lamivudine or tenofovir plus either lamivudine or emtricitabine as nucleoside analogue backbone

Abstract

HIV-infected patients who receive abacavir plus lamivudine respond worse to pegylated interferon plus ribavirin than those who are given tenofovir plus lamivudine or emtricitabine as N(t)RTI backbone, especially in those receiving lower ribavirin doses.

Role of the Pharmacist in Caring for Patients with HIV/AIDS: Clinical Practice Guidelines

“…81,85 Some controversy exists as to whether concomitant abacavir may be associated with a reduced response to pegylated interferon and ribavirin, [86][87][88] but a recent in vitro study showed that the anti-HCV activity of ribavirin was not modified by abacavir. 89 It is important to achieve adequate ribavirin trough levels via weight-based dosing, 85,90 and there is insufficient evidence to recommend avoiding this combination.…”

British HIV Association guidelines for the management of coinfection with HIV‐1 and hepatitis B or C virus 2010

“…Consider liver biopsy particularly for those with genotype 1 or 4 infection where the results of HCV therapy remain Table 3 Interactions between antiretroviral agents and anti-hepatitis C virus (HCV) therapy [186][187][188][189][190][191][192]239] [198,200,201]. The risk-benefit of liver biopsy should be considered in the individual patient.…”

Management of Chronic Hepatitis in Special Hosts and Special Situations: A Consensus Report of the Study Group for Viral Hepatitis of the Turkish Society of Clinical Microbiology and Infectious Diseases

“…HCV ve HIV ile ikili infeksiyonu olan olgularda PegIFN kullanımına bağlı olarak gelişebilecek nötropeni ve trombositopeni, KHC tedavisindekinden farklı değildir. PegIFN dozunun azaltılmasıyla bu durum önlenebilir (169)(170)(171)(172)(173)(174)(175)(176)(177)(178)(179)(180).…”